Quanta has been in the recruiting business for fifteen years, beginning as a specialty recruiting firm for information technology professionals. However, Quanta has expanded over the last decade to a full service recruiting agency, with a proven recruiting, placement, and training method for industrial sectors like biotech. With their highly qualified recruiting staff, Quanta assures hiring companies that they are only receiving the best and brightest biotech professionals. As well, they work hard to make sure that their recruits are prepared for their first day of work.

Quanta’s dynamic recruiting method allows recruits to feel comfortable with their future in the rapidly growing biotech field. Biotech jobs in the future will encompass most professions and connect in some way with all industrial sectors. Biotech production will require project managers, chemical and mechanical engineers, scientists, and quality control and assurance professionals. However, production is only one aspect of this growing industry and there are plenty of positions for permanent and contract recruits through Quanta. Accountants, office managers, business analysts, and many others will have the opportunity to work on the front lines of this rapidly expanding field.

Those breaking into the biotech profession not only need to know about the nature of their specific tasks but how to be well-rounded professionals. Professionals who are recruited by Quanta gain the benefit of QuantaSensus, the agency’s specially designed training suite. Whether it is utilizing resource optimization courses or training on organizational tools, biotech professionals of all types can benefit from the guidance of Quanta’s highly qualified trainers. As well, these training sessions are flexible for the time constraints of the work environment and provide long term tools that allow biotech professionals to succeed in their jobs.

Most of them might seem promising, but the truth is that a good number of these trading & investing opportunities could be extremely risky, while others are simply not as good as they look. That’s why it’s very important to know how to choose among the best especially if you want to day trade them.

When you know how to pick and approach the best hot stock trading opportunities, you are able to generate a consistent and respectable amount of money in a very short period of time.

Experienced day traders recognize that trading hot stocks on momentum can be the fastest way to make money in the stock market, especially on uncertain times like these.

You don’t necessarily have to trade momentum hot stocks all the time. But you can learn how to take advantage of them when you encounter the best opportunities for going long or for shorting them to make money when they are poised to fall down.

If You decide to day trade stocks just keep always in mind that for a trader to survive and be consistently profitable, its necessary to keep things as simple as possible. To much confusion and technical indicators will most of the time make you slow in your decisions and froze you up when a good opportunity is right in front of your screen.

In the end, stock market day trading is all about picking the best daily stock opportunities and following your buy and sell signals with ease and simplicity. Once you learn to master your trading decisions, you can aspire to produce consistent profitable results.

The Divisions of Biotech

A great number of industries are directly influenced by biotechnology, and it would be difficult to mention all of them in a short article. However, to provide a
broader perspective, jobs in biotechnology can be grouped into three functional categories:
Research and development: Considered by some to be the most prestigious division of biotech research and development (R&D) creates the frontiers of
biotechnology and sets the paradigms that influence both humanity and the biotech job market. The three major divisions of biotechnological R&D are research for discoveries, veterinary sciences, and bioinformatics. Jobs in this sector are usually reserved for life scientists.
Clinical research and safety: Once a functional process or product is developed by R&D, the necessity to establish trials to determine the impact of the product or process on public health and safety emerges. Biotechnologists working in this field ensure the safety of biotechnological products and processes.
Compliance: Issues of compliance with respect to biotechnological products and processes—in terms of both quality and standards and rules established by the
state—create openings for biotechnologists.
Openings for biotechnologists are also available in the following specific areas and functional fields:

Medicine and Pharmaceuticals

In this broad field, the following functional areas need biotechnologists:
genetics, including medical genetics, genetic counseling, and genetic nursing
organ transplantation, reproduction, and regenerative medicine
public health and safety, which includes projects ranging from vaccine development to wastewater treatment by bacterial colonies
gene testing and genetic therapy

Agriculture

Under the broad heading of agriculture, the following functional areas rely on the application of biotechnology and consequently are the areas where biotech jobs are to be found:
development of genetically modified variations of plants and seeds development of biological pesticides and nutrition identification and protection of endangered
species, including artificial breeding verification and authentication of costly food products
Bioinformatics
Under this broad heading come:
computational biology
supercomputing
statistical and actuarial functions
data analysis, data transfer, database creation, and other data-related functions

Law

With the rise in the use of biotechnology, openings for biotechnologists have also opened up in the legal field. Openings are principally located in the following functional areas:
patent specialties and litigation
academia
ethical, social, and legal issues
forensic sciences, including gene testing for identification purposes

Guided Missile Development and Space Technology

Biotechnologists are required in organizations engaged in manufacturing guided missiles and space vehicles. Functional areas include:
creation of closed artificial environments
creation of life-supporting equipment and systems
research into the effects of space on biological systems
cybernetics

Engineering

There are many opportunities for biotechnologists in the field of engineering. Biotechnologists working in this area may be involved in:
designing bioprocessing containers and equipment
creating new energy sources such as biofuels
biomedical engineering

Education

Obviously a need for biotechnologists who can teach will always exist. Types of opportunities available in biotechnological education reflect the needs of

universities and traditional academic structure.
Besides the above fields, there are myriad other divisions of applied biotechnology, including life-science research, anthropology, history, military, bio-science

communication, and chemical manufacturing.

Biotech Job Designations

Biotech job designations are as varied as the fields in which biotechnology finds application. Though designations can reflect the imagination of the employer, some standard, industry-recognized designations that are related to biotechnology or the application of biotechnical knowledge are veterinary assistant, veterinarian, technician, technologist, chemist, pharmacologist, laboratory technician, chemical technician, engineer, computer system analyst, health service worker, physician, biological scientist, biotechnologist, and agricultural technician. One’s designation depends on the organization, industry, and sector in which he or she works, and job designations can be superficially misleading.

Most eyes are set on big companies with strong drug development channels and low chances of patent expirations, but the real value behind these mergers is still unknown, as, in the past, they have not shown important additional value in terms of R&D productivity. In fact, these mergers will produce more mergers and acquisitions activity, because some of the secondary units of these companies may need to be parted with. A big plus could be the increase in bargaining capability with payors and government, making this a strategic move leading to the strengthening of the big pharma family, but not benefitting the patients.

An additional aspect that is very clear is the move of big pharma to biotech. The blockbuster model is not expected to disappear, as it has been responsible for turning the pharma industry into a high profit margin one. However, it may shift from a small molecule-based blockbuster model to a biologics based one, since many have seen the huge opportunity behind biologics, and super mergers and acquisitions have been developing activities related to the pharma-biotech field. Also, manufacturing and commercialization of biosimilars is more complicated than it is for small molecule generic drugs, minimizing the generic threat for biologics.

One thing is clear, any pharmaceutical consultant can confidently state that big pharma is becoming big biopharma. Big pharma is consolidating space by acquiring past partnerships and alliances with biotech companies. It can be seen that many of the acquired biotech companies had partnered before with their acquirer, and current alliances make acquisitions easier because of cultural compatibility and knowledge of the company.

Licensing deals attract acquirers and provide a revenue source to maintain business activity. Novel technology, biologics product portfolio and scientific talent are attractive factors drawing super mergers and acquisitions towards the pharma-biotech sphere. These advantages, added to the fact that many biotech companies’ valuation has declined in about 30%, present a tempting possibility of acquisition rather than to try to negotiate complex licensing deals.

Besides the super mergers and acquisitions taking place within the pharma biotech sphere, many biogenerics and biosimilars are expected to enter the market in the next years, and big biotech companies need to add new products to their portfolios and expand their current lines to stay competitive. These could also become preferred targets for big pharma.

The acquisition of so many biotech companies makes it difficult for small and medium ones to make it through, as investors will opt for the acquisition as a safe way out. However, these seldom succeed due to management inefficiency, which must be expert in order to do well at the right time and in the right way.

It is important to realize that these small biotech companies have great capacity to attract the best scientific talent because of their flexible and entrepreneurial culture, so, any attempt to force onto them the big pharma work culture will surely create a clash. These should be kept as independent business units and research entities, while big pharma centers on commercialization.

The pharma industry should focus on acquiring small and medium biotech companies instead of uniting into super mergers and acquisitions, saving both the struggling biotech industry and pharma.